Interleukin 6 and C-reactive protein in esophageal cancer

Clin Chim Acta. 2012 Oct 9;413(19-20):1583-90. doi: 10.1016/j.cca.2012.05.009. Epub 2012 May 16.

Abstract

Esophageal cancer (EC) is one of the most aggressive malignant tumors of the gastrointestinal tract. It is well known that cancer initiation and tumor development are closely linked with inflammation. C-reactive protein (CRP) and interleukin-6 (IL-6) are acute-phase proteins involved in cancer development. It was suggested that CRP and IL-6 play potential roles in the growth and progression of malignant tumors, including EC. The aim of the study was to describe the significance of IL-6 and CRP in the development of esophageal cancer and to assess the potential role of their serum levels as prognostic indicators of EC patient's survival.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / blood*
  • Adenocarcinoma / complications
  • Adenocarcinoma / drug therapy
  • Antineoplastic Agents / therapeutic use
  • Biomarkers, Tumor / blood
  • C-Reactive Protein / metabolism*
  • Carcinoma, Squamous Cell / blood*
  • Carcinoma, Squamous Cell / complications
  • Carcinoma, Squamous Cell / drug therapy
  • Esophageal Neoplasms / blood*
  • Esophageal Neoplasms / complications
  • Esophageal Neoplasms / drug therapy
  • Gene Expression
  • Humans
  • Inflammation / blood*
  • Inflammation / complications
  • Inflammation / drug therapy
  • Interleukin-6 / blood*
  • Prognosis
  • Risk Factors

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Interleukin-6
  • C-Reactive Protein